Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer

Patient Education and Counseling

Volumn 89, Issue 1, 2012, Pages 102-108

  Gerber, David E ^a,b   Hamann, Heidi A ^b   Rasco, Drew W ^a,c   Woodruff, Sharon ^b   Lee, Simon J Craddock ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c South Texas Accelerated Research Therapeutics (START)   (United States)

Author keywords

Dallas, TX; Maintenance chemotherapy; Non small cell lung cancer; Patient perceptions; Thematic analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPREHENSION; DISEASE CONTROL; FEMALE; HEALTH CARE DELIVERY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL DECISION MAKING; ONCOLOGY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PERCEPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; STATISTICAL MODEL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMPREHENSION; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PATIENT PREFERENCE; PERCEPTION; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUINAZOLINES; TEXAS; TREATMENT OUTCOME;

EID: 84866601154     PISSN: 07383991     EISSN: 18735134     Source Type: Journal    
DOI: 10.1016/j.pec.2012.04.013     Document Type: Article

References (31)

1. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
2. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
3. Klein R., Wielage R., Muehlenbein C., Liepa A.M., Babineaux S., Lawson A., et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010, 5:1263-1272.
4. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
5. Belani C.P., Waterhouse D.M., Ghazal H., Ramalingam S.S., Bordoni R., Greenberg R., et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:abstr 7506.
6. Perol M., Chouaid C., Milleron B.J., Gervais R., Barlesi F., Westeel V., et al. Maintenance with either gemcitabine of erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010, 28:abstr 7507.
7. Sun J.M., Park J.O., Won Y.W., Kim J.H., Yun J., Lee J., et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 2010, 5:540-545.
8. Gerber D.E., Rasco D.W., Le P., Yan J., Dowell J.E., Xie Y. Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol 2011, 6:365-371.
9. Haines I. Rituximab maintenance therapy for follicular lymphoma. Lancet 2011, 377:1151.
10. Murphy C., Khasraw M., Seidman A. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 2010, 122:177-179.
11. Stinchcombe T.E., Socinski M.A. Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. J Thorac Oncol 2011, 6:174-182.
12. Jalal S.I., Ademuyiwa F.O., Hanna N.H. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol 2009, 21:110-115.
13. Cappuzzo F., Coudert B.P., Wierzbicki R., Wu Y.-L., Gonzalez E.E., Davidson N., et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol 2009, 4:S289. [Abstract A2.1].
14. Barbour R.S. Making sense of focus groups. Med Educ 2005, 39:742-750.
15. Krueger R., Casey M. Focus groups: a practical guide for applied research 2000, Sage Publications, Thousand Oaks, CA.
16. Nelson J.E., Gay E.B., Berman A.R., Powell C.A., Salazar-Schicchi J., Wisnivesky J.P. Patients rate physician communication about lung cancer. Cancer 2011, 117:5212-5220.
17. U.S. Census State and County QuickFacts: Dallas County, TX. Available at: [accessed 21.02.12]. http://quickfacts.census.gov/qfd/states/48/48113.html.
18. Rasco D.W., Yan J., Xie Y., Dowell J.E., Gerber D.E. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010, 5:1529-1535.
19. Ritchie J.E., Herscovitch F., Norfor J.B. Beliefs of blue collar workers regarding coronary risk behaviors. Health Educ Res 1994, 9:95-103.
20. George M., Margolis M.L. Race and lung cancer surgery - a qualitative analysis of relevant beliefs and management preferences. Oncol Nurs Forum 2010, 37:740-748.
21. Silvestri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Brit Med J 1998, 317:771-775.
22. Yorio J.T., Xie Y., Yan J., Gerber D.E. Lung cancer diagnostic and treatment intervals in the united states: a health care disparity?. J Thorac Oncol 2009, 4:1322-1330.
23. Miles M.B., Huberman A.M. Qualitative data analysis 1994, Sage, Newbury Park, CA.
24. Creswell J. Qualitative inquiry and research design: choosing among five traditions 1988, Sage Publications, Thousand Oaks, CA.
25. Mays N., Pope C. Rigour and qualitative research. Brit Med J 1995, 311:109-112.
26. Cohen D.J., Crabtree B.F. Evaluative criteria for qualitative research in health care: controversies and recommendations. Ann Fam Med 2008, 6:331-339.
27. Zeliadt S.B., Ramsey S.D., Penson D.F., Hall I.J., Ekwueme D.U., Stroud L., et al. Why do men choose one treatment over another?. Cancer 2006, 106:1865-1874.
28. Holmboe E.S., Concato J. Treatment decisions for localized prostate cancer. J Gen Intern Med 2000, 15:694-701.
29. Chapple A., Ziebland S., Herxheimer A., McPherson A., Shepperd S., Miller R. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. Brit J Urol Int 2002, 90:257-264.
30. Jagsi R., Abrahamse P., Morrow M., Griggs J.J., Schwartz K., Katz S.J. Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process. Cancer 2009, 115:1185-1193.
31. Salles G., Seymour J.F., Offner F., López-Guillermo A., Belada D., Xerri L., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.